Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Longeveron Inc. - Class A Common stock
(NQ:
LGVN
)
2.380
-0.060 (-2.46%)
Delayed Quote
Updated: 2:39 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Longeveron Inc. - Class A Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Study Links Cat Parasite to Accelerated Frailty in Aging People
November 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast
November 14, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions
November 13, 2023
Via
Investor Brand Network
Earnings Preview: Longeveron
↗
November 09, 2023
Via
Benzinga
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update
November 10, 2023
Via
Investor Brand Network
Earnings Scheduled For November 10, 2023
↗
November 10, 2023
Companies Reporting Before The Bell • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Sex Hormones Could Influence Alzheimer’s Development, Researchers Say
November 06, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call
November 03, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial
October 30, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
October 24, 2023
Via
Investor Brand Network
Nearly A Third Of Japan’s 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron’s (NASDAQ: LGVN) Cell Therapy Help?
October 24, 2023
--News Direct--
Via
News Direct
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
↗
October 23, 2023
Nations all over the world are getting older, but Japan is leading the charge, with nearly a third of its total population over 65 — making Japan the oldest society in the world.
Via
Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering
October 16, 2023
Via
Investor Brand Network
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
↗
October 13, 2023
Wa’el Hashad, CEO of Longeveron (NASDAQ: LGVN), was a guest recently on Benzinga’s All-Access.
Via
Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering
October 12, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 05, 2023
Via
Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
October 05, 2023
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent...
Via
Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial
October 05, 2023
Via
Investor Brand Network
Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study
↗
October 05, 2023
Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for
Via
Benzinga
Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product
September 27, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
September 15, 2023
Via
Benzinga
Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference
September 14, 2023
Via
Investor Brand Network
Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"
↗
September 14, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions...
Via
Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 12, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 12, 2023
--News Direct--
Via
News Direct
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter
September 11, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
